Epidermal growth factor (EGF) A61G polymorphism and EGF gene expression in normal colon tissue from patients with colorectal cancer

Spindler, Karen‐Lise Garm; Nielsen, Joachim; Ørnskov, Dorthe; Brandslund, Ivan; Jakobsen, Anders

doi:10.1080/02841860701338853

Cited by 32 publications

(23 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These experiments suggest different growth properties in the proximal and distal colon of normal and neoplastic colon tissue. EGF promoter polymorphisms were observed to modulate EGF levels and thought to have effect on susceptibility to various carcinomas but the results are contradictory [30,[57][58]. In the present study we observed a significant association of EGF G61G genotype with rectosigmoid junction and rectal cancers (1.74, 95% CI 1.018-3.0, p=0.04) in total cases and especially in women (4.5, 95% CI 1.2-16.9, p=0.02).…”

Section: Product Of Pcr-rflp Analysis Of Egf A61g (Left) and P53 Arg7mentioning

confidence: 99%

Association of EGF and p53 gene polymorphisms and colorectal cancer risk in the Slovak population

et al. 2014

View full text Add to dashboard Cite

AbstractDuring the transformation process single nucleotide polymorphisms (SNPs) of key genes, such as p53 Arg72Pro or EGF A61G, may mediate various cellular processes. These variants may be associated with colorectal cancer risk (CRC), but conflicting findings have been reported. The purpose of this study was to determine the association of the SNPs in 5′ UTR of EGF A61G and p53 Arg72Pro and CRC in the Slovak population. The present case-control study was carried out in 173 confirmed CRC patients and 303 healthy subjects. Genotyping was performed by PCR-RFLP methods. Significant association was observed between age and CRC risk (p=0.001). Lower CRC risk was seen in younger patients carrying genotype p53 Arg72Pro (0.14; 95% CI 0.02–0.99, p=0.049). Gender-stratified analysis showed a significant inverse association of the polymorphism EGF G61G with CRC risk (0.48; 95% CI 0.2–0.9, p=0.04) only in male patients. Tumour site genotype distribution revealed that female patients with localized colon cancer were significantly associated with p53 Pro72Pro genotype (4.0; 95% CI 1.27–12.7, p=0.04) whereas the cancer of rectosigmoid junction was associated with the EGF G61G genotype (4.5; 95% CI 1.2–16.97, p=0.02). Combination of p53 Arg72Pro or EGF A61G polymorphisms were not associated with CRC risk by using logistic regression.

show abstract

Section: Product Of Pcr-rflp Analysis Of Egf A61g (Left) and P53 Arg7mentioning

confidence: 99%

Association of EGF and p53 gene polymorphisms and colorectal cancer risk in the Slovak population

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Lim et al [24] reported that the ?61G allele was associated with an increased risk of lung cancer compared to the A allele (OR = 2.32, 95% CI: 1.61-3.37). Costa et al [26] reported that the G allele conferred higher risks for glioblastomas ( [28] reported that a significantly lower median age in the A/A group compared to the G/G group, suggesting a later time of diagnosis in the G/G patients with colorectal cancer. Additionally, Shahbazi et al [18] reported that homozygosity for the EGF 61 ?G allele was significantly associated with Breslow thickness (P = 0.045) and with the risk of malignant melanoma (OR = 4.9, 95% CI: 2.3-10.2).…”

Section: Discussionmentioning

confidence: 97%

“…Subsequently, a wide variety of studies have reported that this polymorphism is associated with susceptibility and/or severity or survival outcome to a range of human cancers, such as melanoma [18][19][20], gastric cancer [21,22], cervical cancer [23], lung cancer [24], glioblastoma [25], glioma [26], hepatocellular carcinoma [27], colorectal cancer [28], prostate cancer [29], and esophageal cancer [30,31]. Therefore, we hypothesized that EGF gene polymorphism may modulate the susceptibility to ESCC.…”

Section: Introductionmentioning

confidence: 96%

Association Between Epidermal Growth Factor Polymorphism and Esophageal Squamous Cell Carcinoma Susceptibility

Cui¹,

Pan

et al. 2009

Dig Dis Sci

View full text Add to dashboard Cite

Genetic factors are known to be important in the development of esophageal squamous cell carcinoma (ESCC). Epidermal growth factor (EGF) can activate several signaling pathways leading to proliferation, differentiation, and tumorigenesis of epithelial tissues by binding with its receptor. Interindividual variations in EGF production were genetically contributed to EGF +61 G/A polymorphism. The purpose of this study is to investigate the potential association between EGF gene polymorphism and ESCC in a Chinese population. In this study, we analyzed single nucleotide polymorphism of EGF +61 G/A in 158 patients with ESCC and 212 age- and sex-matched controls in a Chinese population using a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) strategy and DNA sequencing. The variant genotypes of GA/AA were associated with a significantly decreased risk of ESCC compared with the wild-type homozygote GG (OR = 0.657, 95% CI: 0.434-0.996). However, no significant difference was observed between the EGF +61 G/A polymorphism and the risk of ESCC when the analyses were stratified in terms of age, gender, smoking status, different clinical stage, and lymph node status. The EGF +61 G/A polymorphism is associated with ESCC in a Chinese population. Our data suggests that the EGF gene may play a role in the development of ESCC.

show abstract

“…The EGF A+61G polymorphism modulates the transcription of EGF and is associated with EGF serum levels [79,80]. Within the study population of the 130 mCRC drawn from the aforementioned IMCL-0144 study the EGF A+61G polymorphism was significantly associated with PFS.…”

Section: Polymorphisms Within the Egfr Gene And Egf Genementioning

confidence: 95%

Can we predict the response to epidermal growth factor receptor targeted therapy?

et al. 2008

View full text Add to dashboard Cite

Epidermal growth factor receptor (EGFR) targeted therapy interferes with a molecular pathway that significantly regulates tumor growth, progression, and survival. Several clinical trials on EGFR targeted therapy revealed objective responses, and also improved survival in patients with different solid tumors. However, considerable differences in therapeutic efficacy were recognized across patient populations that might rely on specific character

show abstract

Epidermal growth factor (EGF) A61G polymorphism and EGF gene expression in normal colon tissue from patients with colorectal cancer

Cited by 32 publications

References 22 publications

Association of EGF and p53 gene polymorphisms and colorectal cancer risk in the Slovak population

Association of EGF and p53 gene polymorphisms and colorectal cancer risk in the Slovak population

Association Between Epidermal Growth Factor Polymorphism and Esophageal Squamous Cell Carcinoma Susceptibility

Can we predict the response to epidermal growth factor receptor targeted therapy?

Contact Info

Product

Resources

About